SambaEpisode Selected as 'Asia-Pacific Company of the Year' for Two Consecutive Years at International Awards Ceremony

Selection of Outstanding Companies for Business and Licensing This Year

Samsung Bioepis announced on the 26th that it was selected as the 'Company of the Year, Asia-Pacific' and 'Regulatory Achievement of the Year' at the 'Global Generic & Biosimilar Awards 2023' held on the 25th (local time) in Barcelona, Spain.

Samsung Bioepis announced on the 26th that it was selected as the "Company of the Year, Asia-Pacific" and "Regulatory Achievement of the Year" at the "Global Generic & Biosimilar Awards 2023" held in Barcelona, Spain on the 25th (local time). Trophy received by Samsung Bioepis.
[Photo by Samsung Bioepis]

The Global Generic & Biosimilar Awards is an annual ceremony hosted by the pharmaceutical industry information service company Scrip, recognizing companies that have achieved notable management performance in the generic and biosimilar industry.

Samsung Bioepis explained that it received awards in two categories in recognition of its achievements in research and development and commercialization across various fields over the past year. In May, it obtained European marketing authorization for 'Episclis,' a biosimilar of the ultra-expensive rare disease treatment 'Soliris,' and recently, its 'Byooviz,' a biosimilar of 'Lucentis,' received interchangeability designation approval from the U.S. Food and Drug Administration (FDA).

Moreover, in July, it launched 'Hadlima,' a biosimilar of 'Humira,' in the U.S. market. The company stated that based on its experience selling approximately 6.8 million Humira biosimilars in markets outside the U.S. over the past four years, it is striving to expand patient access to treatment.

Meanwhile, Samsung Bioepis was previously awarded 'Biosimilar Initiative of the Year' at the same event in 2020 and 'Company of the Year, Asia-Pacific' in 2022. This year, by being selected again as 'Company of the Year,' it has been recognized as the top industry company in the Asia-Pacific region for two consecutive years.

Samsung Bioepis currently holds 10 biosimilar products and pipelines. Among them, seven products in the fields of autoimmune, oncology, ophthalmology, and hematology have received approval, and three follow-up pipelines have completed clinical trials and are undergoing approval procedures. The approved products include biosimilars of Enbrel, Remicade, Humira, Herceptin, Avastin, Lucentis, and Soliris. The products that have completed clinical trials and are in the process of approval are biosimilars of Eylea, Prolia, and Stelara.

Meanwhile, at this awards ceremony, Switzerland's Sandoz won three awards including 'Company of the Year.' India's Biocon was selected as 'M&A Company of the Year,' and Israel's Teva was chosen as 'Corporate Social Responsibility Leader of the Year.'

This content was produced with the assistance of AI translation services.